164 related articles for article (PubMed ID: 23816044)
41. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
Wang Y; Ke H
Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
[TBL] [Abstract][Full Text] [Related]
42. Characterization of non-lipid autotaxin inhibitors.
Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
[TBL] [Abstract][Full Text] [Related]
43. Structure-based design of novel boronic acid-based inhibitors of autotaxin.
Albers HM; Hendrickx LJ; van Tol RJ; Hausmann J; Perrakis A; Ovaa H
J Med Chem; 2011 Jul; 54(13):4619-26. PubMed ID: 21615078
[TBL] [Abstract][Full Text] [Related]
44. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
45. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
Durgam GG; Virag T; Walker MD; Tsukahara R; Yasuda S; Liliom K; van Meeteren LA; Moolenaar WH; Wilke N; Siess W; Tigyi G; Miller DD
J Med Chem; 2005 Jul; 48(15):4919-30. PubMed ID: 16033271
[TBL] [Abstract][Full Text] [Related]
46. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
47. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
48. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
Vlasceanu A; Jessing M; Kilburn JP
Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
[TBL] [Abstract][Full Text] [Related]
49. Considering autotaxin inhibitors in terms of 2D-QSAR and 3D-mapping- review and evaluation.
Katsamakas S; Bermperoglou E; Hadjipavlou-Litina D
Curr Med Chem; 2015; 22(12):1428-61. PubMed ID: 25723504
[TBL] [Abstract][Full Text] [Related]
50. Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great
Lei H; Guo M; Li X; Jia F; Li C; Yang Y; Cao M; Jiang N; Ma E; Zhai X
J Med Chem; 2020 Jul; 63(13):7326-7346. PubMed ID: 32479084
[TBL] [Abstract][Full Text] [Related]
51. Autotaxin and LPA receptor signaling in cancer.
Houben AJ; Moolenaar WH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):557-65. PubMed ID: 22002750
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis.
Uranbileg B; Ito N; Kurano M; Kano K; Uchida K; Sumitani M; Aoki J; Yatomi Y
Sci Rep; 2021 Feb; 11(1):3984. PubMed ID: 33597645
[TBL] [Abstract][Full Text] [Related]
53. Mechanism of DNA cleavage by the DNA/RNA-non-specific Anabaena sp. PCC 7120 endonuclease NucA and its inhibition by NuiA.
Meiss G; Gimadutdinow O; Haberland B; Pingoud A
J Mol Biol; 2000 Mar; 297(2):521-34. PubMed ID: 10715218
[TBL] [Abstract][Full Text] [Related]
54. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
[TBL] [Abstract][Full Text] [Related]
55. Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay.
Li Z; Cai YH; Cheng YK; Lu X; Shao YX; Li X; Liu M; Liu P; Luo HB
J Chem Inf Model; 2013 Apr; 53(4):972-81. PubMed ID: 23517293
[TBL] [Abstract][Full Text] [Related]
56. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
Barbayianni E; Kaffe E; Aidinis V; Kokotos G
Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
[TBL] [Abstract][Full Text] [Related]
57. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
58. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
59. "Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.
Stylianaki EA; Magkrioti C; Ladopoulou EM; Papavasileiou KD; Lagarias P; Melagraki G; Samiotaki M; Panayotou G; Dedos SG; Afantitis A; Aidinis V; Matralis AN
Eur J Med Chem; 2023 Mar; 249():115130. PubMed ID: 36702053
[TBL] [Abstract][Full Text] [Related]
60. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
